top of page
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Search
Kadimastem and NLS Pharmaceutics Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement
The equity financing is at a 10% premium to the market share price [1] ZÜRICH, Switzerland, March 31, 2025 - NLS Pharmaceutics Ltd. ...
Mar 317 min read
Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment
Companies Advance Collaborative Clinical Development of iTOL-102: A Potential Cure for Diabetes Without the Need for Chronic Life-long...
Feb 258 min read
NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies
Revolutionizing Diabetes Treatment : Introduction of cutting-edge, multi-targeted innovation to transform diabetes care. Diabetes more...
Feb 108 min read
Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS
Kadimastem Approaches Final Steps for Securing Merger Completion ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL— January 16th 2025 — NLS...
Jan 167 min read
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting
Was sold at Share Price of $3.10, Representing 48% Above the Market Share Price as of Jan 6, 2025 ZURICH, SWITZERLAND and NESS ZIONA,...
Jan 87 min read
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger
The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical...
Dec 31, 20247 min read
NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment
This submission comes after successful INTERACT meeting with the FDA earlier this year. NLS Pharmaceutics and Kadimastem working to close...
Dec 19, 20248 min read
The BIRD Foundation has Approved an Additional Payment to Kadimastem and Miami Based iTolerance Inc. from the Total Grant for the Continued Co-Development of the Innovative Treatment for Diabetes
The Additional Payment is for the Progress Presented by the Companies in the Development of the Treatment Ness Ziona, Israel, November...
Nov 27, 20246 min read
Vote of Confidence by Major Kadimastem Shareholder in the Merger Transaction with Swiss Biopharma Company NLS Pharmaceutics
Prof. Michel Revel, a company founder, who serves as the company's chief scientist, director and substantial shareholder who invented a...
Nov 17, 20246 min read
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement
ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL /November 5th, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS"), a biopharmaceutical...
Nov 5, 20245 min read
Kadimastem completes another stage towards the merger with NLS Pharmaceutics, which has Regained Full Compliance with Nasdaq Listing Requirements
Ness Ziona, Israel October 29, 2024 -Kadimastem Ltd (“KDST.TA”, “Kadimastem”), a clinical-stage cell therapy company developing and...
Oct 29, 20244 min read
Kadimastem Ltd. and NLS Pharmaceutics Announce Binding Term Sheet to Merge
The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical...
Jul 29, 20246 min read
The World Prestigious Diabetes Research Institute, University of Miami, Announces Kadimastem's Joint Project as Breakthrough Transplantation Approach for the Treatment of Type 1 Diabetes
The results were presented at the 84th scientific conference of the American Diabetes Association (ADA) Kadimastem Ltd. (TASE: KDST),...
Jun 23, 20245 min read
Kadimastem Takes Another Step Towards Signing the Merger Agreement with Nasdaq Listed IMCC
Kadimastem reveals that the company with which it has signed a non-binding memorandum of understanding for a merger is IMCC (NASDAQ:...
Feb 28, 20243 min read
Kadimastem advances towards Nasdaq: Company Signs a Memorandum of Understanding to Merge with a Company traded on the Nasdaq
Kadimastem shareholders to hold 88% of the shares of the combined company post-merger Kadimastem Ltd. (TASE: KDST), a leading cell...
Feb 15, 20243 min read
Kadimastem Receives Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in India
The patent approval in India strengthens the company’s global position in the diabetes field Ness Ziona, Israel, February 7th, 2024 ,...
Feb 7, 20244 min read
A peer reviewed article on Kadimastem's AstroRx® Cryopreserved off the Shelf Cell Product for the Treatment of ALS was Published in the Journal of Clinical Toxicology
The publication presents the development and preclinical safety of Kadimastem's off the shelf AstroRx ("thaw to inject") cell product in...
Jan 25, 20243 min read
Kadimastem and iTolerance Complete Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting with the U.S. FDA
Companies Advancing Joint Clinical Development of a Potential Cure for Diabetes Without the Need for Chronic Suppression of the Immune...
Jan 22, 20244 min read
Kadimastem and iTolerance Submit INTERACT Request with FDA for Potential Cure for Type 1 Diabetes
Kadimastem and iTolerance signed a collaboration agreement several months ago to co-develop cell technology as a potential cure for...
Nov 7, 20234 min read
Kadimastem Receives US Patent for Its Cell Selection & Enrichment Technology Used to Develop IsletRx
The patent approval in the US strengthens the company’s global leadership position in the diabetes field Ness Ziona, Israel, June 20th,...
Jun 20, 20234 min read
bottom of page